Gina Z. D'Amato, MD

Gina Z. D’Amato, MD, a professor of clinical medicine, assistant director of clinical research, medical director of the Nurse Practitioner Oncology Fellowship Program, and medical director of patient education at the Sylvester Comprehensive Cancer Center and the Miller School of Medicine at the University of Miami.

Articles by Gina Z. D'Amato, MD

Gina Z. D’Amato, MD, professor of clinical medicine, assistant director, clinical research, medical director, Nurse Practitioner Oncology Fellowship Program, medical director, patient education, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami

Dr D’Amato on the Rationale for Studying Olaparib/Temozolomide in Leiomyosarcoma

ByGina Z. D'Amato, MD

August 28th 2025

Gina Z. D’Amato, MD, discusses the rationale for investigating olaparib plus temozolomide in previously treated advanced uterine leiomyosarcoma.

Supporting Community Practice Through Collaboration

ByShreyaskumar R. Patel, MD, MD Anderson Cancer Center,Priscilla Merriam, MD,Richard F. Riedel, MD,Gina Z. D'Amato, MD

July 15th 2025

Panelists discuss how communication between community oncologists and academic centers is essential for advancing gastrointestinal stromal tumor (GIST) treatment through clinical trial participation, molecular analysis, and the promising future of personalized therapy based on individual tumor mutation profiles.

Dr D'Amato on Efficacy Data With Olaparib Plus Temozolomide in Advanced Uterine Leiomyosarcoma

ByGina Z. D'Amato, MD

July 10th 2025

Gina Z. D’Amato, MD, shares her interpretation of efficacy outcomes from the negative Alliance A092104 trial in advanced uterine leiomyosarcoma.

Evolving Gastrointestinal Stromal Tumor Treatment Landscape

ByShreyaskumar R. Patel, MD, MD Anderson Cancer Center,Priscilla Merriam, MD,Richard F. Riedel, MD,Gina Z. D'Amato, MD

July 8th 2025

Panelists discuss how newer clinical trials such as PEAK and INSIGHT are investigating combination therapies and mutation-specific treatment approaches to overcome secondary resistance mutations, while also exploring pan-KIT inhibitors and senescence-targeting strategies to improve outcomes.

Ripretinib Use in Advanced Gastrointestinal Stromal Tumors

ByShreyaskumar R. Patel, MD, MD Anderson Cancer Center,Priscilla Merriam, MD,Richard F. Riedel, MD,Gina Z. D'Amato, MD

July 8th 2025

Panelists discuss how most gastrointestinal stromal tumor (GIST) patients can tolerate approved agents with proper adverse effect management, the efficacy data from the INVICTUS and INTRIGUE trials that led to ripretinib's approval, and the unique adverse effects such as alopecia that distinguish ripretinib from other therapies.

Treating Patients With Gastrointestinal Stromal Tumors

ByShreyaskumar R. Patel, MD, MD Anderson Cancer Center,Priscilla Merriam, MD,Richard F. Riedel, MD,Gina Z. D'Amato, MD

June 27th 2025

Panelists discuss how patient adherence to kinase inhibitors is crucial for disease control, requiring proactive adverse effect management, careful radiological monitoring, and strategies such as dose escalation to maximize treatment duration and effectiveness.

Gastrointestinal Stromal Tumor Treatment Landscape

ByShreyaskumar R. Patel, MD, MD Anderson Cancer Center,Priscilla Merriam, MD,Richard F. Riedel, MD,Gina Z. D'Amato, MD

June 27th 2025

Panelists discuss how standard-of-care treatment follows NCCN guidelines with sequential kinase inhibitor therapy (imatinib, sunitinib, regorafenib, ripretinib), emphasizing that maintaining some form of kinase inhibition is always preferable to no treatment even after progression.

Role of Mutations in Gastrointestinal Stromal Tumors

ByShreyaskumar R. Patel, MD, MD Anderson Cancer Center,Priscilla Merriam, MD,Richard F. Riedel, MD,Gina Z. D'Amato, MD

June 20th 2025

Panelists discuss how mutational testing is critical for gastrointestinal stromal tumor (GIST) management, with different genetic alterations determining treatment sensitivity and the importance of understanding both primary drivers and secondary resistance mutations that develop over time.

Overview of Gastrointestinal Stromal Tumors

ByShreyaskumar R. Patel, MD, MD Anderson Cancer Center,Priscilla Merriam, MD,Richard F. Riedel, MD,Gina Z. D'Amato, MD

June 20th 2025

Panelists discuss how gastrointestinal stromal tumors (GISTs) are the most common sarcoma with specific genetic mutations, requiring comprehensive mutational analysis to guide treatment decisions and understand both primary and secondary resistance patterns.